GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma

NCT01991158 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

DRUG: High dose of methotrexate
DRUG: Gemcitabine
DRUG: Pegaspargase
DRUG: Dexamethasone

Sponsor

Sun Yat-sen University

Collaborators

[object Object]